Instylla is focused on developing next-generation liquid embolics for interventional radiology, with initial clinical applications in interventional oncology and peripheral hemostasis.
| Website | https://www.instylla.com/ |
| Revenue | $7.4 million |
| Employees | 75 (57 on RocketReach) |
| Founded | 2017 |
| Address | 201 Burlington Rd, Bedford, Massachusetts 01730, US |
| Phone | +1 617-510-3859 |
| Technologies |
JavaScript
,
HTML
,
PHP
+15 more
(view full list)
|
| Industry | Medical Equipment Manufacturing, Biotechnology, Science and Engineering, Commercial, Medical Device, Health Care |
| Keywords | Interventional Radiology, Radiology Devices, Interventional Medicine, Oncology Devices, Interventional Oncology, Cancer Treatment, Drug Delivery Systems, Bleeding Control, Next Generation Medical Devices, Medical Technology, Medical Innovation, Minimally Invasive Medical Devices, Advanced Medical Devices, Medical Device Development, Clinical Trials |
| Competitors | Medtronic, Boston Scientific, Abbott, Terumo, CR Bard - Europe, Middle East and Africa (EMEA), Zimmer Biomet, Johnson & Johnson, Smith+Nephew, Stryker, Hologic, Inc. +40 more (view full list) |
Looking for a particular Instylla employee's phone or email?
The Instylla annual revenue was $7.4 million in 2026.
Sean Boyle is the CEO of Instylla.
57 people are employed at Instylla.
Instylla is based in Bedford, Massachusetts.